494 related articles for article (PubMed ID: 21279819)
1. Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
Okada M; Satake A; Kaida K; Taniguchi K; Yoshihara S; Ikegame K; Tamaki H; Soma T; Fujimori Y; Ogawa H
Int J Hematol; 2011 Feb; 93(2):243-246. PubMed ID: 21279819
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
4. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
5. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
6. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
9. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy for CML: nilotinib comes of age.
Davies J
Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
[No Abstract] [Full Text] [Related]
12. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
13. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
14. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
15. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
[TBL] [Abstract][Full Text] [Related]
16. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
17. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T; Ashihara E; Kimura S
Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
[TBL] [Abstract][Full Text] [Related]
19. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Nardi V; Azam M; Daley GQ
Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
